# Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

> **NCT01559090** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 17 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** MEDI-546
- **DRUG:** MEDI-546
- **DRUG:** MEDI-546

## Key facts

- **NCT ID:** NCT01559090
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-20
- **Primary completion:** 2014-08-19
- **Final completion:** 2017-02-21
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01559090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01559090, "Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01559090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*